Article
Prostaglandin E <sub>2</sub> promotes <i> <scp>MYCN</scp> </i> non‐amplified neuroblastoma cell survival <i>via</i> β‐catenin stabilization
30 Sept 2014
Abstract excerpt
Amplification of MYCN is the most well-known prognostic marker of neuroblastoma risk classification, but still is only observed in 25% of cases. Recent evidence points to the cyclic adenosine monophosphate (cAMP) elevating ligand prostaglandin E2 (PGE2 ) and β-catenin as two novel players in neuroblastoma. Here, we aimed to define the potential role of PGE2 and cAMP and its potential interplay with β-catenin,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
